Synergistic Treatment and Prevention of Surgery-Induced Cachexia through AI-Powered Personalized Nutrition and Advanced Technologies
Legal Citation
Summary of the Inventive Concept
The present disclosure relates to a comprehensive system for treating and preventing surgery-induced cachexia, leveraging synergistic combinations of AI, IoT, blockchain, and nanotechnology with specialized immunonutrition supplements to provide personalized and targeted interventions.
Background and Problem Solved
Surgery-induced cachexia is a severe and debilitating condition that affects millions of patients worldwide. The original patent disclosed compositions and methods for treating or preventing cachexia using specialized immunonutrition supplements. However, these approaches have limitations, such as lack of personalization, limited efficacy, and inadequate data management. The present inventive concept addresses these limitations by integrating advanced technologies to provide a more effective and comprehensive solution.
Detailed Description of the Inventive Concept
The system comprises a specialized immunonutrition supplement administered to a patient, which is combined with an AI-powered personalized nutrition planning module that generates a customized dietary plan based on the patient's genomic profile and medical history. Additionally, the system incorporates IoT-enabled sensors to track the patient's nutritional intake and physiological responses, which are integrated with a blockchain-based health record system to ensure secure and transparent data management. Furthermore, the system includes a composition for preventing or treating surgery-induced cachexia, comprising a synergistic blend of L-arginine, omega-3 fatty acids, and vitamin A, and a nanocarrier system for targeted delivery of the nutrients to the affected tissues.
Novelty and Inventive Step
The present inventive concept introduces a novel and non-obvious combination of AI, IoT, blockchain, and nanotechnology with specialized immunonutrition supplements, providing a synergistic and personalized approach to treating and preventing surgery-induced cachexia. The inventive concept's novelty lies in its ability to integrate multiple advanced technologies to provide a comprehensive solution that addresses the limitations of existing approaches.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include using machine learning algorithms to predict the risk of cachexia, or incorporating decentralized blockchain-based networks to share and analyze data from multiple healthcare providers. Variations of the composition may include different ratios of L-arginine, omega-3 fatty acids, and vitamin A, or the use of alternative nanocarrier systems.
Potential Commercial Applications and Market
The present inventive concept has significant commercial potential in the healthcare industry, particularly in the fields of oncology, surgery, and nutrition. The system's ability to provide personalized and targeted interventions makes it an attractive solution for healthcare providers and patients seeking more effective and efficient treatments for surgery-induced cachexia.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical nutrition, oncological supportive care, and personalized medical technology with a focus on surgical patient nutritional interventions and cachexia management
Person of Ordinary Skill (PHOSITA) Profile
A medical nutritionist or clinical researcher with expertise in nutritional supplementation, surgical patient care, advanced medical technologies, and interdisciplinary approaches to patient treatment strategies
Obviousness Rationale
A PHOSITA would recognize that integrating advanced technologies with established nutritional intervention strategies represents a natural progression in personalized medical care. The core nutritional supplement composition remains substantially similar to the source patent, with technological augmentation providing enhanced monitoring and personalization. The fundamental scientific principles of targeted nutritional supplementation for surgery-induced cachexia remain consistent, with technological additions representing predictable evolutionary improvements.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,525 |
|---|---|
| Title | Treatment or prevention of surgery-induced cachexia and/or expression of myeloid-derived suppressor cells and pro-inflammatory cytokines |
| Assignee(s) | SOCIÉTÉ DES PRODUITS NESTLÉ S.A. |